{"ticker": {"uuid": "cb9cf828-1bea-4eb3-b7d0-f285264c4591", "symbol": "LTRN", "name": "Lantern Pharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group", "summary": "New to The Street will broadcast Show #761 as sponsored programming across Bloomberg Television in the U.S., Latin America, and MENA. The program features executive interviews with Sagtec Global, Virtuix Holdings, Lantern Pharma, and YY Group Holding, discussing their growth stra", "url": "https://www.newswire.com/news/new-to-the-street-show-761-to-broadcast-across-bloomberg-u-s-latin-america-and", "source_name": "Newswire.com", "published_at": "2026-07-11T19:41:09", "published_display": "11 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Launches ZetaOmics\u2122 \u2014 an Autonomous, Intelligent \"Computational Biologist\" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lantern-pharma-launches-zetaomics-autonomous-113000970.html", "source_name": "Business Wire", "published_at": "2026-07-08T11:30:00+00:00", "published_display": "08 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma\u2019s ZetaOmics turns plain-English questions into cancer analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUS1KNFZSVlh2U2t1czY3NkhKaDJyUFpxRVhpS09jM0k3MjRMcEhvMm9KdEZnNnB3RU8tVFBVdkREUGlfYUJmLV9NcnBBMmtHSl9SSWpKYnZwa1FyTExELWJtZmJBUjZocEdXbWJEeXBhUVFrdzcwdEI1TF8xckFPWklNOS1zamJIQlVhMndHY0Y4QjU5WHpGLW9VRDVuUzd3djZSaXVGaXZoVG5sMURKMHJRekg5MmlTM1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T11:30:00+00:00", "published_display": "08 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Launches ZetaOmics\u2122 \u2014 an Autonomous, Intelligent \u201cComputational Biologist\u201d That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer", "summary": "Lantern Pharma has launched ZetaOmics, an AI-driven \"Computational Biologist\" module as part of its withZeta.ai platform, designed to bring expert-grade bioinformatics and biostatistics to all cancer types, particularly rare and pediatric cancers. ZetaOmics autonomously designs e", "url": "https://www.businesswire.com/news/home/20260708109056/en/Lantern-Pharma-Launches-ZetaOmics-an-Autonomous-Intelligent-Computational-Biologist-That-Brings-Expert-Grade-Bioinformatics-Biostatistics-Reasoning-to-Every-Cancer", "source_name": "Business Wire", "published_at": "2026-07-08T11:40:50", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (Nasdaq:LTRN) - Analyse des actions", "summary": "This Simply Wall St report analyzes Lantern Pharma (LTRN), highlighting its focus on oncology drug discovery and development using AI. The company has a low financial score due to forecasted declining earnings, minimal revenue, and current unprofitability, yet it boasts a strong ", "url": "https://simplywall.st/fr/stocks/us/pharmaceuticals-biotech/nasdaq-ltrn/lantern-pharma?invalidate=", "source_name": "Simply Wall Street", "published_at": "2026-07-07T06:09:29", "published_display": "07 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma, Inc. Actuals & Estimates (BOATS:LTRN)", "summary": "This article provides an overview of Lantern Pharma Inc. (LTRN) on the BOATS exchange, detailing its financials, analyst estimates, and historical stock performance. It includes information on earnings, revenue, net income, employee count, and answers frequently asked questions a", "url": "https://www.tradingview.com/symbols/BOATS-LTRN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:35", "published_display": "26 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Lantern Pharma Inc. (LTRN) stock, including analyst opinions, historical performance data, and key financial metrics. It covers the current stock price, volatility, market capitalization, upcoming earnings reports, an", "url": "https://www.tradingview.com/symbols/NASDAQ-LTRN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:38:54", "published_display": "26 Jun 2026 06:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Lantern Pharma Inc. SEC Filing", "summary": "This article announces an SEC filing by Lantern Pharma Inc. (LTRN) for Form EFFECT, indicating a neutral impact and sentiment. The filing pertains to a Notice of Effectiveness for Form S-1, with an effective date of June 18, 2026. The article also provides key company details, re", "url": "https://www.stocktitan.net/sec-filings/LTRN/effect-lantern-pharma-inc-sec-filing-dbd8155f6e5f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:10:42", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Lantern Pharma Inc (LTRN), showing its current stock price and market capitalization. It highlights that key valuation data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The content primarily serve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T03:41:20", "published_display": "18 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lantern Pharma Inc (LTRN), including its current stock price, market cap, and a breakdown of various technical indicators and moving averages. It highlights that while support and resistance data are not disclosed, the indicators show", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/technical", "source_name": "TradingKey", "published_at": "2026-06-18T01:41:21", "published_display": "18 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Lantern Pharma Inc (LTRN), including future EPS and revenue growth estimates. Based on one analyst, the stock has a \"Buy\" rating with a target price indicating significant upside. The report also covers recent EPS performance and upc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:41:20", "published_display": "18 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Lantern Pharma Inc (LTRN), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the current stock price, market cap, and links to ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:52", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lantern Pharma Inc's (LTRN) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The piece includes current stock information such as price", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:51", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk", "summary": "Lantern Pharma (NASDAQ: LTRN) has filed an S-1 registration statement for the resale of 2.24 million shares of common stock tied to warrants from a May 2026 financing. The company will not receive proceeds from these resales, but may acquire up to $5.1 million if all warrants are", "url": "https://www.stocktitan.net/sec-filings/LTRN/s-1-lantern-pharma-inc-files-ipo-registration-statement-303e26eba7e3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:40:14", "published_display": "12 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did LTRN Stock Surge 18% In Pre-Market Today?", "summary": "Lantern Pharma Inc. (LTRN) saw its stock surge by 18% in pre-market trading after the FDA cleared its Investigational New Drug application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers. STAR-001 was discovered us", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-ltrn-stock-surge-in-pre-market-today/cZ3HcItRIlx", "source_name": "Stocktwits", "published_at": "2026-06-12T06:40:14", "published_display": "12 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Reports HARMONIC\u2122 Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer", "summary": "Lantern Pharma reported clinical data from its Phase 2 HARMONIC\u2122 trial for LP-300 in EGFR Exon 21 L858R-mutant NSCLC, showing that progression-free survival benefit for LP-300 deepens with treatment duration, especially in the L858R subgroup. Patients treated through six cycles a", "url": "https://www.biospace.com/press-releases/lantern-pharma-reports-harmonic-data-showing-lp-300-progression-free-survival-benefit-deepens-with-treatment-duration-in-egfr-exon-21-l858r-lung-cancer", "source_name": "BioSpace", "published_at": "2026-06-03T03:09:44", "published_display": "03 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma stock jumps on lung cancer trial survival data", "summary": "Lantern Pharma Inc. (NASDAQ:LTRN) saw its shares rise after reporting extended survival data from its Phase 2 lung cancer trial. Patients treated with LP-300 plus chemotherapy achieved a median progression-free survival of 8.9 months, with over 70% experiencing tumor reduction. T", "url": "https://m.investing.com/news/stock-market-news/lantern-pharma-stock-jumps-on-lung-cancer-trial-survival-data-93CH-4722149?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-02T14:40:35", "published_display": "02 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lantern-pharma-says-longer-lp-125051379.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:50:51+00:00", "published_display": "02 Jun 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma reports trial data for lung cancer treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdWR5azJHWWxMT0s5ZGJyNVV1NEl2Y1Fxbjk0d2lKemNubzF4dHlON2owWVVzWUNyQ1RZLW5QdlNURmhLTXBjWHRNZFEwM0NlVnJTblo0QlYwanhHNVhERW9rYWdOTUJYX1NhZFFlTWdoaHF5RGRNTEZ2SmhIcmI2RnNNMGRwQVU0V2RpanJYbXJwNXhjTzdSOEE0U2tLTHJWSEJfTEt2RFZTTXB3dC1BSTJYOVJuQ2s?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Shares Promising Phase 2 Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQOXdIU1pnSlpPX2xMSUxtNmZ6MnBLQVlBUWRZRGprT1VzSFNMYnE2TmM5SWRRWXZSc0NnSXlJR2MzRUZZUXJfNXdraFBrZk9UdThEa21LcndzWmNFNWlVWjFDRGtncUNtRkgtaUZFYmJrdVp5SDl1QTV3ZDFRYXpPR2wtX01RUTU1MENiOS1IMHFBdUtsQjJVMURDckpEQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) shares Harmonic LP-300 Phase 2 trial presentation in 8-K", "summary": "Lantern Pharma Inc. (LTRN) filed an 8-K to furnish an investor-style presentation about its Harmonic\u2122 Phase 2 clinical trial for the LP-300 product candidate. The presentation, used on June 1, 2026, is attached as Exhibit 99.1 and is designated as \"furnished\" rather than \"filed,\"", "url": "https://www.stocktitan.net/sec-filings/LTRN/8-k-lantern-pharma-inc-reports-material-event-e14346c74292.html", "source_name": "Stock Titan", "published_at": "2026-06-02T00:10:29", "published_display": "02 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN - Lantern Pharma Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for Lantern Pharma Inc. (LTRN), including its current stock price, financial metrics, recent news, and insider transaction details. It highlights the company's focus on AI and machine learning for drug development, particularl", "url": "https://finviz.com/stock?t=LTRN", "source_name": "Finviz", "published_at": "2026-05-30T02:09:37", "published_display": "30 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN)", "summary": "This article provides recent news and financial updates for Lantern Pharma Inc. (NASDAQ: LTRN). Key announcements include successful FDA Type C meeting results for its HARMONIC\u2122 Phase 2 trial of LP-300, the report of Q1 2026 financial results, and two recent direct offerings tota", "url": "https://www.chartmill.com/stock/quote/LTRN/news", "source_name": "ChartMill", "published_at": "2026-05-29T13:38:49", "published_display": "29 May 2026 13:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN Technical Analysis | Trend, Signals & Chart Patterns | LANTERN PHARMA INC (NASDAQ:LTRN)", "summary": "This article provides a technical analysis of LANTERN PHARMA INC (NASDAQ:LTRN), assigning it an overall technical rating of 8 out of 10. Both medium and short-term trends are positive, with the stock currently trading near the high end of its monthly range. However, the analysis ", "url": "https://www.chartmill.com/stock/quote/LTRN/technical-analysis", "source_name": "ChartMill", "published_at": "2026-05-27T00:10:46", "published_display": "27 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Q1 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/2c536d01-3944-3136-8f31-dafcaf334f74/lantern-pharma-%28ltrn%29-q1-2025.html", "source_name": "Motley Fool", "published_at": "2026-05-21T14:39:34+00:00", "published_display": "21 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC\u2122 Phase 2 Trial of LP-300 in Never-Smokers with NSCLC", "summary": "Lantern Pharma announced that the FDA had no objections to its proposed amendments for the HARMONIC\u2122 Phase 2 trial of LP-300. The amendments include focusing enrollment on patients with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lantern-pharma-announces-successful-outcome-113000880.html", "source_name": "Market source", "published_at": "2026-05-19T18:10:21", "published_display": "19 May 2026 18:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "Lantern Pharma reported its Q1 2026 financial results, showcasing a 47% reduction in R&D spend and a 27% decrease in net loss while advancing multiple clinical programs and launching its multi-agentic AI platform, withZeta.ai. The company also announced a strategic plan to separa", "url": "https://www.biospace.com/press-releases/lantern-pharma-reports-first-quarter-2026-financial-results-and-provides-business-updates", "source_name": "BioSpace", "published_at": "2026-05-18T08:40:43", "published_display": "18 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Stock Price, Quote, News & History", "summary": "This article provides a comprehensive overview of Lantern Pharma Inc. (LTRN) stock, including its current price ($2.99), market performance, key statistics, and recent news. It highlights the company's focus on developing oncology drug candidates using its AI platform and details", "url": "https://www.benzinga.com/quote/LTRN", "source_name": "Benzinga", "published_at": "2026-05-16T19:40:06", "published_display": "16 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Revenue N/A -- What's the Valuation Signal?", "summary": "Lantern Pharma Inc. (LTRN) reported a positive Q1 2026, with an EPS of -$0.30, beating analyst estimates of -$0.36. The company significantly reduced its net loss by 27% year-over-year and cut R&D expenses by 47%. Key milestones include FDA clearance for a pediatric CNS trial and", "url": "https://www.gurufocus.com/news/8863933/lantern-pharma-ltrn-q1-2026-eps-030-beats-est-036-revenue-na-whats-the-valuation-signal-gf-score-33100-gf-value-na", "source_name": "GuruFocus", "published_at": "2026-05-15T22:40:12", "published_display": "15 May 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (NASDAQ: LTRN) raises $4.4M and plans withZeta.ai spinout", "summary": "Lantern Pharma reported a Q1 2026 net loss of $3.33 million, a reduction from the previous year, with cash and equivalents totaling $6.3 million. Despite a recent $4.4 million equity raise, the company noted \"substantial doubt\" about its ability to continue as a going concern, an", "url": "https://www.stocktitan.net/sec-filings/LTRN/10-q-lantern-pharma-inc-quarterly-earnings-report-b2f3703811e6.html", "source_name": "Stock Titan", "published_at": "2026-05-15T19:40:12", "published_display": "15 May 2026 19:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern to carve out withZeta.ai cancer AI platform into new entity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPb2NCM0RCdGZJLXFsNEV2WEdyWjRtOUZJSHMxdngwdkVLQ1h1a0xIQ01FcEZfdzNXcEF3ZGhnbVB5UVN4alRZSHFQZUYtUWxLRFV2RWEtbDl1clNoT01kV3NJN1RwUHpSSHI1UXFoWHBMVDFnZllOdUhua0NINUVFb0NlNllBT2dfSDZ2WXhQRFBZYi1QZ2NUTkdmSGZSVnBDc1NZRURIQ3ljaWlqLXNvRzUtbVBWdGFlYXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxObm1tSzNPaGtMLVptNk9HRlpYSVpaWW1nTDlHMXBTcUtLa3FIT0hYRDZhUE9KY2FqVE9OT3NrM1pUUC1sVmhnbnVkUWt0cWxMeTUzZ3RiRTAzNXdHNlJzN2VUQ0plcGdWLURHSUVsNXRneUtJUFp6T2RmM2N5S1dsUnptVVM3QTItVUU2bmxJcTc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lantern Pharma (NASDAQ: LTRN) closes $4.4M offering and outlines AI spin-out", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxONHF0b2pOdXBlMUk1cEhKODNPb3dGRXBUN0JMYk1XSm9CU21XLXNSbG53TnEwQkRBekZWM1FLS2xVbTNIc2pPU3dNNzN3TlNpdThmTFN4U1R3Wm84X1dKdG5iQ2pSNXphTzZHQWU0S1FlQzBiamVzUHdtc29zbjBxbC05X3Uyb3FPNlVwOXVuZUx5NWhmMmRsX0Y2bkMybWxzZmc0VmxpaDdjS0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOYm1KYzdrUTZ4d3ZvdEdrTm1wRlpqcFJuVFZxNGlldnp4S1dUNS1PMy1ZOHgyTDZ0SGE2d3EwOWN4NWRkQ2tJUHlFXzVSal94eVFFWi1TRWpNUHJac3ZidHVtVVo5eDA3aUhfODlnOTFsN3hacnZLZF9McFJtNGlLSVl3V29wVWtEV2R0YjBoU2gxM1R6dUMyNEctMG1paDNkQ005NUNSM1lNb1hRRGJUQl9vV0psOGdzM29yTUwzMzNBR1l5eUVYUHdUems0aGh5eWtDREZmS0RxWkdxa0s2aVFEVVpzTHJXM2FIbjF0QjlpZ0xUYldWUHk3OFZMZlk2ZjlBTFlBM3dxT1dDUjdoVVdPYlRSbFg3Y3c5bHNhU2xEMVlOODd0NVdrWWk?oc=5", "source_name": "Business Wire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) director adds shares and long-dated stock warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPWWlzQTFMdTRXaTJISnQ4YVl3a2JNVDZsNFBRY0trWVVfWUVhc1Z4YjFYVE9pR003TU1VeURkQXJGMGZ5N0FlemE1UXk2cHcwX3hSMXB5N3cxVE82OXFJMG1RNUlHWWhNUU1uYWU3UEZoZ3dOcEs3UUZfd0dOZ2M2MklyeHFqU01EODJyOUYySDNpYzlNWFlLMU4xRDBJT2xxOWp1NXJ4SWZhT0htcU1SU0V3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Lee Schalop Acquires 48,544 Shares of Lantern Ph", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPVkZ6bkFfSUtIWkw3MElxSnlUNGxKdWNMbnRLVUVhSTkwNnRSdWYxejgzS2Q4eEVib3k2M2lCS0NPajI3ejdRcnEzYU5QYjQweDlSN1V4VEhCZDlQaDdmZVIxX1FhTXE5MHB2TmtiUUZoVjhyVEVUS0hsc2ZVeFVEYld6eTRtUVo3U2dtMjJYaFB5UnQxN3diTEJERjNxRld6R1JXaU5DN2JIZGRYRUxNc3JucnQwWTM3MmQzanpmTk5fbTdz?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOclNLLVhVY1BBaUVva2JZdVF0NkxnM04xYTJtbWRxX3JiYkZDeXR0ai1GcmNoMjJxdE8tNzFKOUZ3a2p0eXZlcjFfZEE4STJlSXJlVHAyOWpXV0JrUXNrTC1tN25HV2toUXZoV3Y3TnhHU25QR2I4Qkl1WHRhYnYzYjdyU1hsWmJtM1hpU0xoaDFwbDg5UkxnZFEwdnJhTEp1UURxbzUwdDhLWXB0YjVwRXVIZ21VUEU0TVRBRXRudTc0b0lDNU9BcWlmejFCS2ZrWVhqZ2JmNzFEUXE5V2x3WUp3Z1JxYXEyWjhQRTlaSFZNXzViUGJ5MDI0aXl1M3MzUmUwM2t2NVN1TTdMSGJVZGpxLUVnMHVWOU43bzRn?oc=5", "source_name": "Business Wire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/street-broadcasts-show-746-tonight-165500187.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-25T16:55:00+00:00", "published_display": "25 Apr 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/correction-join-lantern-pharma-april-132500789.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-24T13:25:00+00:00", "published_display": "24 Apr 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/join-lantern-pharma-april-30-130000977.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-24T13:00:00+00:00", "published_display": "24 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lantern Pharma denies CEO departure claim, calls report false", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQeVpMdnd2MEFzbmhQYkY3dXpwZERkT0t6NElhZ2tFTTJfejYtMThrWVFoTmFqRDNybVl1STkyeDZZYlQtTkZpbzA1ZE9aOW5oSFdUanQtWGNBbjlwaDBkdXpxTmVHeS12Y2l4dlVCSG9zM3BGUmZhb2RMNEVjZ2I1T01ITE5xLXQ0dkt5VWZod1MyclRwcVRRYkkzLXU1V3RUdVdfQWd1ZURGWkhGZGtjUnlFLTBvM0Rr?oc=5", "source_name": "Investing.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Stock Drops as Investors Weigh Financial Results and Clinical Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1PNkRoNkh4TF94VGtZNTFBZ3FLUl9FejRYam9ySy1md1R1UUhXSmlfTkVXenhKT0M2cXBzQjdrNWhjUlNZSW05ME5jcENXSkVuLVRrcEhxMUVhVTV3ZmtrSmpYOFJ1cmdKQ3JTNXVkVF9vVFBkRWZKTkRR?oc=5", "source_name": "timothysykes.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOeGVURmJYckg4NF9UenQ3VjFBbk9Hak1jMEktcEk1WW42cF9BRkpnaXFmYVpUN0tldWl6YmpUV0Vpd0FkNmxZX295cHVZaExJc1VzalFwZ0hSYzU3ai1LaF9Yc1NrWlBlSENjTFNwN2ZBQVBCSW9SQmlsX2ZaWDM3M1VjWnhILWhuZDRN?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOc1U5b2lFU2VDbEhvdFVYaWpDN1dnMFh1Ql9JX1ZzNjU4OFF5QWpoMkFaOXdwSDMxZkRzUWtrQ055aEg4Zmk3czh1Q1pHZnRJMWh6bTdrR1p1SjZoZUlhU3Z5SHZZM1dFRlJSQmlHQXNCSUcxUTNaRHFmVlVIaV9xTnhPOTc?oc=5", "source_name": "Market source", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two stocks to invest in the future of pharma | 2025-09-29 | Investing News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOenEyN1RrOFFUb21FYlNoellZSWxMYnBHamRXaU5lTktVUGJQUV81aEVDZzdGbnczV3hlaWhreG1LUmhkVzRzQ2pvRFE3RzV4SDVEYzRPS3c0NGxITHRlUmh1UzgxcGxpMnNDMGQ0NTAyTG1mV1JxRXNBdkZiUXliYlhueGtpS094TkE?oc=5", "source_name": "Stockhouse", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9OU0FqTGdzOGgya0J0Szg1YlN2MUpQSFBqbjJEUm9idjBoclMtNy1pZ3ZnN3RBcmk4djE3eE9WWXJ5WUJfdnRoNWVhOHVXS245M3dV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:08:47+00:00", "published_display": "25 Apr 2025 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Announces Extension of Existing Share Repurchase Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQNlNlX2txQy1Eb1FzcFY5MktjOVdOaTdJMVRsRk5LR3hiVjhJV2k2bUlqQzU2RmRxTDBhaE1hRVFYaDN3NXZudVphR1U0YWJ6ZzZoVTMtSkwyQXFNWnJVdHl2N2NXZlVrRDlsTENaOEFaZVlfdlFueS1zcXZ1QTgxZWFudVNEQnFvM3ZXZms4OVpmUjBCekphay1KS2U?oc=5", "source_name": "BioSpace", "published_at": "2022-03-22T07:00:00+00:00", "published_display": "22 Mar 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Stock Price, News & Analysis $LTRN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBnOXhzX1pkeWw0UElVM0tlSFdZMWZzd0VFQVZlNVo4RVVQaGpLNGs3YTl2MjdXMWJ6dml2NWpnTVRYU2wyUkpwX2ZjMXp6UWxyb01FNUM1bGlQUQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-07-01T22:33:14+00:00", "published_display": "01 Jul 2020 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group", "summary": "New to The Street will broadcast Show #761 as sponsored programming across Bloomberg Television in the U.S., Latin America, and MENA. The program features executive interviews with Sagtec Global, Virtuix Holdings, Lantern Pharma, and YY Group Holding, discussing their growth stra", "url": "https://www.newswire.com/news/new-to-the-street-show-761-to-broadcast-across-bloomberg-u-s-latin-america-and", "source_name": "Newswire.com", "published_at": "2026-07-11T19:41:09", "published_display": "11 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Launches ZetaOmics\u2122 \u2014 an Autonomous, Intelligent \"Computational Biologist\" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/lantern-pharma-launches-zetaomics-autonomous-113000970.html", "source_name": "Business Wire", "published_at": "2026-07-08T11:30:00+00:00", "published_display": "08 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma\u2019s ZetaOmics turns plain-English questions into cancer analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUS1KNFZSVlh2U2t1czY3NkhKaDJyUFpxRVhpS09jM0k3MjRMcEhvMm9KdEZnNnB3RU8tVFBVdkREUGlfYUJmLV9NcnBBMmtHSl9SSWpKYnZwa1FyTExELWJtZmJBUjZocEdXbWJEeXBhUVFrdzcwdEI1TF8xckFPWklNOS1zamJIQlVhMndHY0Y4QjU5WHpGLW9VRDVuUzd3djZSaXVGaXZoVG5sMURKMHJRekg5MmlTM1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T11:30:00+00:00", "published_display": "08 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Launches ZetaOmics\u2122 \u2014 an Autonomous, Intelligent \u201cComputational Biologist\u201d That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer", "summary": "Lantern Pharma has launched ZetaOmics, an AI-driven \"Computational Biologist\" module as part of its withZeta.ai platform, designed to bring expert-grade bioinformatics and biostatistics to all cancer types, particularly rare and pediatric cancers. ZetaOmics autonomously designs e", "url": "https://www.businesswire.com/news/home/20260708109056/en/Lantern-Pharma-Launches-ZetaOmics-an-Autonomous-Intelligent-Computational-Biologist-That-Brings-Expert-Grade-Bioinformatics-Biostatistics-Reasoning-to-Every-Cancer", "source_name": "Business Wire", "published_at": "2026-07-08T11:40:50", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (Nasdaq:LTRN) - Analyse des actions", "summary": "This Simply Wall St report analyzes Lantern Pharma (LTRN), highlighting its focus on oncology drug discovery and development using AI. The company has a low financial score due to forecasted declining earnings, minimal revenue, and current unprofitability, yet it boasts a strong ", "url": "https://simplywall.st/fr/stocks/us/pharmaceuticals-biotech/nasdaq-ltrn/lantern-pharma?invalidate=", "source_name": "Simply Wall Street", "published_at": "2026-07-07T06:09:29", "published_display": "07 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma, Inc. Actuals & Estimates (BOATS:LTRN)", "summary": "This article provides an overview of Lantern Pharma Inc. (LTRN) on the BOATS exchange, detailing its financials, analyst estimates, and historical stock performance. It includes information on earnings, revenue, net income, employee count, and answers frequently asked questions a", "url": "https://www.tradingview.com/symbols/BOATS-LTRN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:35", "published_display": "26 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a detailed forecast and price target for Lantern Pharma Inc. (LTRN) stock, including analyst opinions, historical performance data, and key financial metrics. It covers the current stock price, volatility, market capitalization, upcoming earnings reports, an", "url": "https://www.tradingview.com/symbols/NASDAQ-LTRN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T06:38:54", "published_display": "26 Jun 2026 06:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Lantern Pharma Inc. SEC Filing", "summary": "This article announces an SEC filing by Lantern Pharma Inc. (LTRN) for Form EFFECT, indicating a neutral impact and sentiment. The filing pertains to a Notice of Effectiveness for Form S-1, with an effective date of June 18, 2026. The article also provides key company details, re", "url": "https://www.stocktitan.net/sec-filings/LTRN/effect-lantern-pharma-inc-sec-filing-dbd8155f6e5f.html", "source_name": "Stock Titan", "published_at": "2026-06-22T10:10:42", "published_display": "22 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Lantern Pharma Inc (LTRN), showing its current stock price and market capitalization. It highlights that key valuation data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The content primarily serve", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T03:41:20", "published_display": "18 Jun 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Lantern Pharma Inc (LTRN), including its current stock price, market cap, and a breakdown of various technical indicators and moving averages. It highlights that while support and resistance data are not disclosed, the indicators show", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/technical", "source_name": "TradingKey", "published_at": "2026-06-18T01:41:21", "published_display": "18 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Lantern Pharma Inc (LTRN), including future EPS and revenue growth estimates. Based on one analyst, the stock has a \"Buy\" rating with a target price indicating significant upside. The report also covers recent EPS performance and upc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:41:20", "published_display": "18 Jun 2026 01:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Lantern Pharma Inc (LTRN), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the current stock price, market cap, and links to ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:52", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lantern Pharma Inc's (LTRN) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The piece includes current stock information such as price", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ltrn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:51", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk", "summary": "Lantern Pharma (NASDAQ: LTRN) has filed an S-1 registration statement for the resale of 2.24 million shares of common stock tied to warrants from a May 2026 financing. The company will not receive proceeds from these resales, but may acquire up to $5.1 million if all warrants are", "url": "https://www.stocktitan.net/sec-filings/LTRN/s-1-lantern-pharma-inc-files-ipo-registration-statement-303e26eba7e3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:40:14", "published_display": "12 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did LTRN Stock Surge 18% In Pre-Market Today?", "summary": "Lantern Pharma Inc. (LTRN) saw its stock surge by 18% in pre-market trading after the FDA cleared its Investigational New Drug application for STAR-001, allowing the company to begin a Phase 1 pediatric clinical trial for central nervous system cancers. STAR-001 was discovered us", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-ltrn-stock-surge-in-pre-market-today/cZ3HcItRIlx", "source_name": "Stocktwits", "published_at": "2026-06-12T06:40:14", "published_display": "12 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Reports HARMONIC\u2122 Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer", "summary": "Lantern Pharma reported clinical data from its Phase 2 HARMONIC\u2122 trial for LP-300 in EGFR Exon 21 L858R-mutant NSCLC, showing that progression-free survival benefit for LP-300 deepens with treatment duration, especially in the L858R subgroup. Patients treated through six cycles a", "url": "https://www.biospace.com/press-releases/lantern-pharma-reports-harmonic-data-showing-lp-300-progression-free-survival-benefit-deepens-with-treatment-duration-in-egfr-exon-21-l858r-lung-cancer", "source_name": "BioSpace", "published_at": "2026-06-03T03:09:44", "published_display": "03 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma stock jumps on lung cancer trial survival data", "summary": "Lantern Pharma Inc. (NASDAQ:LTRN) saw its shares rise after reporting extended survival data from its Phase 2 lung cancer trial. Patients treated with LP-300 plus chemotherapy achieved a median progression-free survival of 8.9 months, with over 70% experiencing tumor reduction. T", "url": "https://m.investing.com/news/stock-market-news/lantern-pharma-stock-jumps-on-lung-cancer-trial-survival-data-93CH-4722149?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-02T14:40:35", "published_display": "02 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lantern-pharma-says-longer-lp-125051379.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:50:51+00:00", "published_display": "02 Jun 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma reports trial data for lung cancer treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPdWR5azJHWWxMT0s5ZGJyNVV1NEl2Y1Fxbjk0d2lKemNubzF4dHlON2owWVVzWUNyQ1RZLW5QdlNURmhLTXBjWHRNZFEwM0NlVnJTblo0QlYwanhHNVhERW9rYWdOTUJYX1NhZFFlTWdoaHF5RGRNTEZ2SmhIcmI2RnNNMGRwQVU0V2RpanJYbXJwNXhjTzdSOEE0U2tLTHJWSEJfTEt2RFZTTXB3dC1BSTJYOVJuQ2s?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Shares Promising Phase 2 Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQOXdIU1pnSlpPX2xMSUxtNmZ6MnBLQVlBUWRZRGprT1VzSFNMYnE2TmM5SWRRWXZSc0NnSXlJR2MzRUZZUXJfNXdraFBrZk9UdThEa21LcndzWmNFNWlVWjFDRGtncUNtRkgtaUZFYmJrdVp5SDl1QTV3ZDFRYXpPR2wtX01RUTU1MENiOS1IMHFBdUtsQjJVMURDckpEQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) shares Harmonic LP-300 Phase 2 trial presentation in 8-K", "summary": "Lantern Pharma Inc. (LTRN) filed an 8-K to furnish an investor-style presentation about its Harmonic\u2122 Phase 2 clinical trial for the LP-300 product candidate. The presentation, used on June 1, 2026, is attached as Exhibit 99.1 and is designated as \"furnished\" rather than \"filed,\"", "url": "https://www.stocktitan.net/sec-filings/LTRN/8-k-lantern-pharma-inc-reports-material-event-e14346c74292.html", "source_name": "Stock Titan", "published_at": "2026-06-02T00:10:29", "published_display": "02 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN - Lantern Pharma Inc Stock Price and Quote", "summary": "This article provides comprehensive stock information for Lantern Pharma Inc. (LTRN), including its current stock price, financial metrics, recent news, and insider transaction details. It highlights the company's focus on AI and machine learning for drug development, particularl", "url": "https://finviz.com/stock?t=LTRN", "source_name": "Finviz", "published_at": "2026-05-30T02:09:37", "published_display": "30 May 2026 02:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN)", "summary": "This article provides recent news and financial updates for Lantern Pharma Inc. (NASDAQ: LTRN). Key announcements include successful FDA Type C meeting results for its HARMONIC\u2122 Phase 2 trial of LP-300, the report of Q1 2026 financial results, and two recent direct offerings tota", "url": "https://www.chartmill.com/stock/quote/LTRN/news", "source_name": "ChartMill", "published_at": "2026-05-29T13:38:49", "published_display": "29 May 2026 13:38", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LTRN Technical Analysis | Trend, Signals & Chart Patterns | LANTERN PHARMA INC (NASDAQ:LTRN)", "summary": "This article provides a technical analysis of LANTERN PHARMA INC (NASDAQ:LTRN), assigning it an overall technical rating of 8 out of 10. Both medium and short-term trends are positive, with the stock currently trading near the high end of its monthly range. However, the analysis ", "url": "https://www.chartmill.com/stock/quote/LTRN/technical-analysis", "source_name": "ChartMill", "published_at": "2026-05-27T00:10:46", "published_display": "27 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Q1 2025 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/2c536d01-3944-3136-8f31-dafcaf334f74/lantern-pharma-%28ltrn%29-q1-2025.html", "source_name": "Motley Fool", "published_at": "2026-05-21T14:39:34+00:00", "published_display": "21 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC\u2122 Phase 2 Trial of LP-300 in Never-Smokers with NSCLC", "summary": "Lantern Pharma announced that the FDA had no objections to its proposed amendments for the HARMONIC\u2122 Phase 2 trial of LP-300. The amendments include focusing enrollment on patients with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lantern-pharma-announces-successful-outcome-113000880.html", "source_name": "Market source", "published_at": "2026-05-19T18:10:21", "published_display": "19 May 2026 18:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "Lantern Pharma reported its Q1 2026 financial results, showcasing a 47% reduction in R&D spend and a 27% decrease in net loss while advancing multiple clinical programs and launching its multi-agentic AI platform, withZeta.ai. The company also announced a strategic plan to separa", "url": "https://www.biospace.com/press-releases/lantern-pharma-reports-first-quarter-2026-financial-results-and-provides-business-updates", "source_name": "BioSpace", "published_at": "2026-05-18T08:40:43", "published_display": "18 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc (LTRN) Stock Price, Quote, News & History", "summary": "This article provides a comprehensive overview of Lantern Pharma Inc. (LTRN) stock, including its current price ($2.99), market performance, key statistics, and recent news. It highlights the company's focus on developing oncology drug candidates using its AI platform and details", "url": "https://www.benzinga.com/quote/LTRN", "source_name": "Benzinga", "published_at": "2026-05-16T19:40:06", "published_display": "16 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Revenue N/A -- What's the Valuation Signal?", "summary": "Lantern Pharma Inc. (LTRN) reported a positive Q1 2026, with an EPS of -$0.30, beating analyst estimates of -$0.36. The company significantly reduced its net loss by 27% year-over-year and cut R&D expenses by 47%. Key milestones include FDA clearance for a pediatric CNS trial and", "url": "https://www.gurufocus.com/news/8863933/lantern-pharma-ltrn-q1-2026-eps-030-beats-est-036-revenue-na-whats-the-valuation-signal-gf-score-33100-gf-value-na", "source_name": "GuruFocus", "published_at": "2026-05-15T22:40:12", "published_display": "15 May 2026 22:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (NASDAQ: LTRN) raises $4.4M and plans withZeta.ai spinout", "summary": "Lantern Pharma reported a Q1 2026 net loss of $3.33 million, a reduction from the previous year, with cash and equivalents totaling $6.3 million. Despite a recent $4.4 million equity raise, the company noted \"substantial doubt\" about its ability to continue as a going concern, an", "url": "https://www.stocktitan.net/sec-filings/LTRN/10-q-lantern-pharma-inc-quarterly-earnings-report-b2f3703811e6.html", "source_name": "Stock Titan", "published_at": "2026-05-15T19:40:12", "published_display": "15 May 2026 19:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern to carve out withZeta.ai cancer AI platform into new entity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPb2NCM0RCdGZJLXFsNEV2WEdyWjRtOUZJSHMxdngwdkVLQ1h1a0xIQ01FcEZfdzNXcEF3ZGhnbVB5UVN4alRZSHFQZUYtUWxLRFV2RWEtbDl1clNoT01kV3NJN1RwUHpSSHI1UXFoWHBMVDFnZllOdUhua0NINUVFb0NlNllBT2dfSDZ2WXhQRFBZYi1QZ2NUTkdmSGZSVnBDc1NZRURIQ3ljaWlqLXNvRzUtbVBWdGFlYXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxObm1tSzNPaGtMLVptNk9HRlpYSVpaWW1nTDlHMXBTcUtLa3FIT0hYRDZhUE9KY2FqVE9OT3NrM1pUUC1sVmhnbnVkUWt0cWxMeTUzZ3RiRTAzNXdHNlJzN2VUQ0plcGdWLURHSUVsNXRneUtJUFp6T2RmM2N5S1dsUnptVVM3QTItVUU2bmxJcTc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (NASDAQ: LTRN) closes $4.4M offering and outlines AI spin-out", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxONHF0b2pOdXBlMUk1cEhKODNPb3dGRXBUN0JMYk1XSm9CU21XLXNSbG53TnEwQkRBekZWM1FLS2xVbTNIc2pPU3dNNzN3TlNpdThmTFN4U1R3Wm84X1dKdG5iQ2pSNXphTzZHQWU0S1FlQzBiamVzUHdtc29zbjBxbC05X3Uyb3FPNlVwOXVuZUx5NWhmMmRsX0Y2bkMybWxzZmc0VmxpaDdjS0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOYm1KYzdrUTZ4d3ZvdEdrTm1wRlpqcFJuVFZxNGlldnp4S1dUNS1PMy1ZOHgyTDZ0SGE2d3EwOWN4NWRkQ2tJUHlFXzVSal94eVFFWi1TRWpNUHJac3ZidHVtVVo5eDA3aUhfODlnOTFsN3hacnZLZF9McFJtNGlLSVl3V29wVWtEV2R0YjBoU2gxM1R6dUMyNEctMG1paDNkQ005NUNSM1lNb1hRRGJUQl9vV0psOGdzM29yTUwzMzNBR1l5eUVYUHdUems0aGh5eWtDREZmS0RxWkdxa0s2aVFEVVpzTHJXM2FIbjF0QjlpZ0xUYldWUHk3OFZMZlk2ZjlBTFlBM3dxT1dDUjdoVVdPYlRSbFg3Y3c5bHNhU2xEMVlOODd0NVdrWWk?oc=5", "source_name": "Business Wire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) director adds shares and long-dated stock warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPWWlzQTFMdTRXaTJISnQ4YVl3a2JNVDZsNFBRY0trWVVfWUVhc1Z4YjFYVE9pR003TU1VeURkQXJGMGZ5N0FlemE1UXk2cHcwX3hSMXB5N3cxVE82OXFJMG1RNUlHWWhNUU1uYWU3UEZoZ3dOcEs3UUZfd0dOZ2M2MklyeHFqU01EODJyOUYySDNpYzlNWFlLMU4xRDBJT2xxOWp1NXJ4SWZhT0htcU1SU0V3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Lee Schalop Acquires 48,544 Shares of Lantern Ph", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPVkZ6bkFfSUtIWkw3MElxSnlUNGxKdWNMbnRLVUVhSTkwNnRSdWYxejgzS2Q4eEVib3k2M2lCS0NPajI3ejdRcnEzYU5QYjQweDlSN1V4VEhCZDlQaDdmZVIxX1FhTXE5MHB2TmtiUUZoVjhyVEVUS0hsc2ZVeFVEYld6eTRtUVo3U2dtMjJYaFB5UnQxN3diTEJERjNxRld6R1JXaU5DN2JIZGRYRUxNc3JucnQwWTM3MmQzanpmTk5fbTdz?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor", "summary": "", "url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOclNLLVhVY1BBaUVva2JZdVF0NkxnM04xYTJtbWRxX3JiYkZDeXR0ai1GcmNoMjJxdE8tNzFKOUZ3a2p0eXZlcjFfZEE4STJlSXJlVHAyOWpXV0JrUXNrTC1tN25HV2toUXZoV3Y3TnhHU25QR2I4Qkl1WHRhYnYzYjdyU1hsWmJtM1hpU0xoaDFwbDg5UkxnZFEwdnJhTEp1UURxbzUwdDhLWXB0YjVwRXVIZ21VUEU0TVRBRXRudTc0b0lDNU9BcWlmejFCS2ZrWVhqZ2JmNzFEUXE5V2x3WUp3Z1JxYXEyWjhQRTlaSFZNXzViUGJ5MDI0aXl1M3MzUmUwM2t2NVN1TTdMSGJVZGpxLUVnMHVWOU43bzRn?oc=5", "source_name": "Business Wire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/street-broadcasts-show-746-tonight-165500187.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-25T16:55:00+00:00", "published_display": "25 Apr 2026 16:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/correction-join-lantern-pharma-april-132500789.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-24T13:25:00+00:00", "published_display": "24 Apr 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/join-lantern-pharma-april-30-130000977.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-24T13:00:00+00:00", "published_display": "24 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma denies CEO departure claim, calls report false", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQeVpMdnd2MEFzbmhQYkY3dXpwZERkT0t6NElhZ2tFTTJfejYtMThrWVFoTmFqRDNybVl1STkyeDZZYlQtTkZpbzA1ZE9aOW5oSFdUanQtWGNBbjlwaDBkdXpxTmVHeS12Y2l4dlVCSG9zM3BGUmZhb2RMNEVjZ2I1T01ITE5xLXQ0dkt5VWZod1MyclRwcVRRYkkzLXU1V3RUdVdfQWd1ZURGWkhGZGtjUnlFLTBvM0Rr?oc=5", "source_name": "Investing.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Stock Drops as Investors Weigh Financial Results and Clinical Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE1PNkRoNkh4TF94VGtZNTFBZ3FLUl9FejRYam9ySy1md1R1UUhXSmlfTkVXenhKT0M2cXBzQjdrNWhjUlNZSW05ME5jcENXSkVuLVRrcEhxMUVhVTV3ZmtrSmpYOFJ1cmdKQ3JTNXVkVF9vVFBkRWZKTkRR?oc=5", "source_name": "timothysykes.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOeGVURmJYckg4NF9UenQ3VjFBbk9Hak1jMEktcEk1WW42cF9BRkpnaXFmYVpUN0tldWl6YmpUV0Vpd0FkNmxZX295cHVZaExJc1VzalFwZ0hSYzU3ai1LaF9Yc1NrWlBlSENjTFNwN2ZBQVBCSW9SQmlsX2ZaWDM3M1VjWnhILWhuZDRN?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-21T08:00:00+00:00", "published_display": "21 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOc1U5b2lFU2VDbEhvdFVYaWpDN1dnMFh1Ql9JX1ZzNjU4OFF5QWpoMkFaOXdwSDMxZkRzUWtrQ055aEg4Zmk3czh1Q1pHZnRJMWh6bTdrR1p1SjZoZUlhU3Z5SHZZM1dFRlJSQmlHQXNCSUcxUTNaRHFmVlVIaV9xTnhPOTc?oc=5", "source_name": "Market source", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two stocks to invest in the future of pharma | 2025-09-29 | Investing News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOenEyN1RrOFFUb21FYlNoellZSWxMYnBHamRXaU5lTktVUGJQUV81aEVDZzdGbnczV3hlaWhreG1LUmhkVzRzQ2pvRFE3RzV4SDVEYzRPS3c0NGxITHRlUmh1UzgxcGxpMnNDMGQ0NTAyTG1mV1JxRXNBdkZiUXliYlhueGtpS094TkE?oc=5", "source_name": "Stockhouse", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9OU0FqTGdzOGgya0J0Szg1YlN2MUpQSFBqbjJEUm9idjBoclMtNy1pZ3ZnN3RBcmk4djE3eE9WWXJ5WUJfdnRoNWVhOHVXS245M3dV?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:08:47+00:00", "published_display": "25 Apr 2025 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma Announces Extension of Existing Share Repurchase Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQNlNlX2txQy1Eb1FzcFY5MktjOVdOaTdJMVRsRk5LR3hiVjhJV2k2bUlqQzU2RmRxTDBhaE1hRVFYaDN3NXZudVphR1U0YWJ6ZzZoVTMtSkwyQXFNWnJVdHl2N2NXZlVrRDlsTENaOEFaZVlfdlFueS1zcXZ1QTgxZWFudVNEQnFvM3ZXZms4OVpmUjBCekphay1KS2U?oc=5", "source_name": "BioSpace", "published_at": "2022-03-22T07:00:00+00:00", "published_display": "22 Mar 2022 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lantern Pharma (LTRN) Stock Price, News & Analysis $LTRN", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBnOXhzX1pkeWw0UElVM0tlSFdZMWZzd0VFQVZlNVo4RVVQaGpLNGs3YTl2MjdXMWJ6dml2NWpnTVRYU2wyUkpwX2ZjMXp6UWxyb01FNUM1bGlQUQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-07-01T22:33:14+00:00", "published_display": "01 Jul 2020 22:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 57, "sentiment_summary": {"positive": 19, "negative": 3, "neutral": 35, "score": 58, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 19}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 3.6, "latest_week": "2026-07-10", "one_week_move": -9.3, "four_week_move": -7.2, "twelve_week_move": 44.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.000128, "market_dynamics_buy_signal": false, "relative_strength": -9.880002, "fair_value_gap": -10.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.2393, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.3% over one week, -7.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 8}, {"label": "TradingKey", "count": 5}, {"label": "Business Wire", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "BioSpace", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "GuruFocus", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 19}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-9.3% over one week, -7.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group"}], "updated_at": "2026-07-16T00:38:22.340305+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}